Jan Schjøtt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3671487/publications.pdf

Version: 2024-02-01

		567281	501196
51	874	15	28
papers	citations	h-index	g-index
52	52	52	1322
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Second Opinion in Pharmacotherapy of ADHD: Do Not Postpone It!. Clinical Therapeutics, 2022, , .	2.5	O
2	Review of Clinical Questions Submitted to Norwegian Drug Information Centres Concerning Administration and Dosage to Older Patients of Relevance to Patient-Centric Care. Pharmaceutics, 2021, 13, 105.	4. 5	1
3	Ultrasound and microbubble assisted drug delivery – A clinical pharmacological perspective. Pharmacological Research, 2021, 165, 105475.	7.1	2
4	Acute Myocardial Injury in a Patient with Attention Deficit Hyperactivity Disorder and History of Substance Abuse: A Multimodality Imaging Point of View. Journal of Cardiovascular Development and Disease, 2021, 8, 67.	1.6	1
5	Quetiapine, Misuse and Dependency: A Case-Series of Questions to a Norwegian Network of Drug Information Centers. Drug, Healthcare and Patient Safety, 2021, Volume 13, 151-157.	2.5	3
6	Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys. Pharmaceutics, 2021, 13, 2038.	4.5	3
7	Analysis of consensus among drug interaction databases with regard to combinations of psychotropics. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 126-132.	2.5	9
8	Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines. Drug Metabolism and Disposition, 2020, 48, 153-158.	3.3	23
9	Review of Questions Concerning Clinical Drug Interactions in ADHD Treatment From Physicians in Norway. Frontiers in Pharmacology, 2020, 11 , 607915.	3.5	2
10	SafeMotherMedicine: Aiming to Increase Women's Empowerment in Use of Medications During Pregnancy and Breastfeeding. Maternal and Child Health Journal, 2020, 24, 531-536.	1.5	6
11	Perception of prescribing factors and purchase statistics of non-steroidal anti-inflammatory drugs in an orthopedic clinic. BMC Research Notes, 2020, 13, 100.	1.4	0
12	Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. Pharmaceutics, 2020, 12, 141.	4.5	17
13	Disproportionality analysis for identification of drug safety signals in a database shared by the Norwegian network of drug information centres (RELIS). European Journal of Clinical Pharmacology, 2019, 75, 1469-1470.	1.9	2
14	The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes. Current Clinical Pharmacology, 2019, 14, 152-156.	0.6	2
15	Drug information centres and their provision of decision support: The Scandinavian experience. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 489-492.	1.5	4
16	A retrospective comparison of inappropriate prescribing of psychotropics in three Norwegian nursing homes in 2000 and 2016 with prescribing quality indicators. BMC Medical Informatics and Decision Making, 2019, 19, 102.	3.0	6
17	Norwegian drug information centres strongly promote person-centred and personalised medicine: a brief report on the achievements and strategy. EPMA Journal, 2019, 10, 109-114.	6.1	1
18	Stability of Antidepressants and Antipsychotics in Gel Separator Tubes. Therapeutic Drug Monitoring, 2019, 41, 249-250.	2.0	2

#	Article	IF	CITATIONS
19	Distribution of Psychotropic Drugs Into Lipoproteins. Therapeutic Drug Monitoring, 2019, 41, 766-771.	2.0	O
20	Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics, 2019, 41, 806-814.	2.5	3
21	Physicians' questions concerning drug use among older patients: experience from Norwegian drug information centres (RELIS) in the period 2010–2015. Aging Clinical and Experimental Research, 2018, 30, 867-870.	2.9	5
22	Use of References in Responses from Scandinavian Drug Information Centres. Medicines (Basel,) Tj ETQq0 0 0 rg	BT/Qverlo	ock ₂ 10 Tf 50 6
23	Ciprofloxacin and acute aortic valve damage. Medical Hypotheses, 2018, 121, 35.	1.5	7
24	Challenges adhering to a medication regimen following first-time percutaneous coronary intervention: A patient perspective. International Journal of Nursing Studies, 2018, 88, 16-24.	5.6	32
25	Analysis of questions about use of drugs in breastfeeding to Norwegian drug information centres. International Breastfeeding Journal, 2018, 13, 1.	2.6	43
26	Shortage of Digitoxin and Switching to Digoxin in Norway: A Retrospective Study of Blood Samples Submitted to a Clinical Pharmacology Laboratory. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 74-77.	2.5	0
27	Benefits of a national network of drug information centres: RELIS. European Journal of Clinical Pharmacology, 2017, 73, 125-126.	1.9	12
28	Quality assessment of structure and language elements of written responses given by seven Scandinavian drug information centres. European Journal of Clinical Pharmacology, 2017, 73, 623-631.	1.9	6
29	Risk perception regarding drug use in pregnancy. American Journal of Obstetrics and Gynecology, 2017, 216, 375-378.	1.3	41
30	Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway. Journal of the American Geriatrics Society, 2016, 64, 1203-1209.	2.6	20
31	Relationship Between Time Consumption and Quality of Responses to Drug-related Queries: A Study From Seven Drug Information Centers in Scandinavia. Clinical Therapeutics, 2016, 38, 1738-1749.	2.5	8
32	A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release, 2016, 243, 172-181.	9.9	332
33	Physicians' Perception of Teratogenic Risk and Confidence in Prescribing Drugs in Pregnancy—Influence of Norwegian Drug Information Centers. Clinical Therapeutics, 2016, 38, 1102-1108.	2.5	10
34	Drug Information Services Today: Current Role and Future Perspectives in Rational Drug Therapy. Clinical Therapeutics, 2016, 38, 414-421.	2.5	30
35	Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids. Substance Abuse and Rehabilitation, 2015, 6, 131.	4.8	10
36	Liquid chromatography/tandem mass spectrometry method for simultaneous quantification of eight endogenous nucleotides and the intracellular gemcitabine metabolite dFdCTP in human peripheral blood mononuclear cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1001, 212-220.	2.3	22

#	Article	IF	CITATIONS
37	Preanalytical Stability of Gemcitabine and its Metabolite 2′, 2′-Difluoro-2′-Deoxyuridine in Whole Blood—Assessed by Liquid Chromatography Tandem Mass Spectrometry. Journal of Pharmaceutical Sciences, 2015, 104, 4427-4432.	3.3	9
38	Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety, 2014, 6, 89.	2.5	6
39	Factors associated with time consumption when answering drug-related queries to Scandinavian drug information centres: a multi-centre study. European Journal of Clinical Pharmacology, 2014, 70, 1395-1401.	1.9	11
40	Questions about complementary and alternative medicine to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive pilot study. BMC Complementary and Alternative Medicine, 2014, 14, 56.	3.7	5
41	Myocardial injury in a 41-year-old male treated with methylphenidate: a case report. BMC Research Notes, 2014, 7, 480.	1.4	13
42	Teratogenic Risk Perception and Confidence in Use of Medicines in Pairs of Pregnant Women and General Practitioners Based on Patient Information Leaflets. Drug Safety, 2013, 36, 481-489.	3.2	23
43	A short-time model to study relevant indices of cardiotoxicity of doxorubicin in the rat. Toxicology Mechanisms and Methods, 2013, 23, 412-418.	2.7	11
44	A question–answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive study. BMJ Open, 2012, 2, e000642.	1.9	22
45	Which factors predict the time spent answering queries to a drug information centre?. International Journal of Clinical Pharmacy, 2010, 32, 799-804.	1.4	19
46	Drug use in pregnancy—physicians' evaluation of quality and clinical impact of drug information centres. European Journal of Clinical Pharmacology, 2009, 65, 303-308.	1.9	19
47	Hepatitis Caused by Lotusâ€f3?. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 414-416.	2.5	8
48	Advice on Drug Safety in Pregnancy. Drug Safety, 2008, 31, 799-806.	3.2	33
49	Pretreatment with Tamoxifen does not Change Acute Epirubicin Cardiotoxicity in Rats. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 231-234.	2.5	0
50	Quality and impact of problem-oriented drug information: a method to change clinical practice among physicians?. European Journal of Clinical Pharmacology, 2002, 57, 897-902.	1.9	24
51	The possibility of hypersensitivity myocarditis following COVID-19 vaccines: Implications for contrast echocardiography. Cardiology, 0, , .	1.4	2